This table refers to compounds (1) in the general formula,Its pharmaceutically acceptable salts, pharmaceutically acceptable solutions, isopropyl isomers, parathion, flurane, N-oxide, metabolites, polymorphine, use of these compounds in medicine, and intermediaries involved in the preparation of these compounds.The utility model is characterized in that the utility model comprises a pharmaceutically acceptable salt, a corresponding isomer thereof, a sound insulation thereof and a pharmaceutical compound containing the substance, wherein Y-S (O) -n is 0, 1, 2, 3 or 4； m is 0, 1 or 2； R¹ is selected from aryl, heteroaryl, heterocyclyl or C₁₋₆aryl alkyl, wherein said aryl, heteroaryl, heterocyclyl or C₁₋₆aryl alkyl is optionally substituted with one, two or three R¹ᵃ groups,where R¹ᵃ at each occurrence independently represents halogen, C₁₋₄ alkyl,C₁₋₄ haloalkyl,C₃₋₈ cycloalkyl,Heteromorphic, represented group-r1-74955,-C₁₋₄-R¹ᵇ alkyl or -O-C₁₋₄-R¹ᵇ alkyl wherein R¹ᵇ at each occurrence independently represents cyano, nitro, -N (R¹ᶜ) ₂,-OR¹ᶜ,-SR¹ᶜ,-C (O) RC (O) OR-C (O) N (R)-S (O) N (R)-S (O) N (R)o -S (O) R-OC (O) R-OC (O) OR-OC (O) N (R)-N (R) C (O) RN (R) C (O) OR-N (R) C (O) N (R)-N (R) C (3DNR) N (R)wherein each R¹ᶜ is independently hydrogen, C₁₋₄ alkyl,a. Halogenated tar c831832421；R2 is selected from z-rz, where Z is - C (ry) 8322 -,-C (H) (OH)-N (ry)..- that is...-C (RY) O-- yes.-S (O) --S (O) --C (O) - where RY at each occurrence independently represents hydrogen, C₁₋₄ haloalkyl groups,1. Lease of c83218331 and 83242431；or C₁₋₄-hydroxy alkyl； and RZ is aryl or heteroaryl, heterocyclyl wherein said aryl or heteroaryl or heterocyclyl group is optionally substituted with one, two or three RZ¹ groups,In each case, RZ1 is cyanogen, halogen, nitrogen-rz1 7495n-n (RZ1 74955) 83222；-ORZ¹ᵇ,-SRZ¹ᵇ,-C (O) RZ-C (O) ORZ-C (O) N (RZ)-S (O) N (RZ)-S (O) N (RZ)-S (O) RZ-OC (O) RZ-OC (O) ORZ-OC (O) N (RZ)-N (R) C (O) RZ-N (RZ) C (O) ORZ-N (RZ) C (O) N (RZ)-N (RZ) C (3DNRZ) N (R
